merck glp-1 agonist Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies GLP-1 receptor agonist 2 |

Antioxidants may inadvertently reduce ROS below cytotoxic levels, protecting tumour cells rather than eliminating them

Acknowledgements We really thank Genevive Brindle who has performed liquid nitrogen assay and Dr Cyril Bories for advice on behavioral testing

Research concerning acute or chronic toxicity of copper due to its deficiency or excess is growing rapidly and interest in the subject is pervasive [4,5,6,7,8,9,10,11,12]

A new alternative insight of nanoemulsion conjugated with -carrageenan for wound healing study in diabetic mice: in vitro and in vivo evaluation

Shin A, Camilleri M, Kolar G, Erwin P, West CP, Murad MH

The study was published in Proceedings of the National Academy of Sciences on March 4, 2026, and was funded by federal research grants from the National Institutes of Health and private philanthropy